Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 13, 2024 08:00 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics Announces Briquilimab Development Program in Asthma

Expanding Portfolio of Mast Cell Programs with Plans to Initiate a Phase 1b/2a study in Patients with Asthma in Q4 2024Company to Host Key Opinion Leader Webinar on the Potential of Briquilimab in...
May 07, 2024 16:30 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics to Present at Upcoming Investor Conferences in May

REDWOOD CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
April 02, 2024 16:30 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
March 21, 2024 16:30 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

REDWOOD CITY, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
March 19, 2024 08:00 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria

REDWOOD CITY, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
March 15, 2024 08:00 ET | Source: Jasper Therapeutics, Inc.

New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia

Three additional patients with Fanconi Anemia treated with briquilimab prior to stem cell transplantAll six patients with Fanconi Anemia treated with briquilimab achieved full donor engraftment and...
March 04, 2024 07:30 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments

REDWOOD CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
February 26, 2024 16:30 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference

REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
February 23, 2024 08:00 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
February 07, 2024 08:00 ET | Source: Jasper Therapeutics, Inc.

Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference

REDWOOD CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...